Alert detail
FDA Approval: QTERN (DAPAGLIFLOZIN) — Type 4 - New Combination
Policy ID: FDA-NDA209091Specialty: Multi-specialtyAdded: 6/6/2026Effective: 2017-02-27federal register
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.